Treating Hepatitis C with Combination Drug Therapy

A Gilead Sciences patent detailing a method to treat Hepatitis C by combining a specific chemical compound with an NS5a inhibitor.

What it covers

This patent describes a medical treatment for Hepatitis C that uses a two-part drug strategy. It requires the administration of an NS5a inhibitor alongside a specific type of chemical compound known as a nucleoside phosphoramidate prodrug. The patent defines the precise molecular structure of this prodrug, including various side chains and chemical groups that allow the drug to be effective. By combining these two distinct types of inhibitors, the treatment aims to disrupt the Hepatitis C virus's ability to replicate in the human body.

What it doesn't cover

• —Does not cover the use of the phosphoramidate prodrugs as a standalone treatment.
• —Does not cover chemical structures that fall outside the specific R1, R2, R3, R4, R7, and R8 substituent definitions provided.
• —Does not cover treatments for viral infections other than Hepatitis C.
• —Does not cover the synthesis of the NS5a inhibitor itself.

The clever bit

The innovation lies in using a 'prodrug'—a biologically inactive compound that the body converts into the active medicine—specifically designed to bypass the rate-limiting step of drug activation inside the liver cells, which was a major hurdle for earlier nucleoside-based antivirals.

Why it matters

This patent is central to the development of highly effective direct-acting antivirals for Hepatitis C. It represents the shift toward combination therapies that have made Hepatitis C a curable disease rather than a chronic, lifelong condition. The technology is foundational to the commercial success of blockbuster drugs like Sovaldi and Harvoni.

Real-world examples

• 1.Sovaldi (sofosbuvir)
• 2.Harvoni (ledipasvir/sofosbuvir)